Evidence‐practice gaps in <scp>P2Y<sub>12</sub></scp> inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population‐level data linkage in Australia

O. Falster, Michael; L. Schaffer, Andrea; Wilson, Andrew; Nasis, Arthur; Jorm, Louisa; Hay, Melanie; Leeb, Kira; Pearson, Sallie‐Anne; Brieger, David

doi:10.1111/imj.15036

Public

Evidence‐practice gaps in P2Y12 inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population‐level data linkage in Australia

Published in Internal Medicine Journal • Aug 25, 2020

Authors:

Michael O. Falster

Andrea L. Schaffer

Andrew Wilson

Abstract

Abstract Background P2Y 12 inhibitor therapy is recommended for 12 months in patients hospitalised for acute myocardial infarction (AMI) unless the bleeding risk is high. Aims To describe real‐world use of P2Y 12 inhibitor therapy following AMI hospitalisation. Methods We used population‐level linke...

Subject

Medicine

Interquartile range

Clopidogrel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!